Objective: Rheumatoid arthritis is treated with aceclofenac as the first line of treatment. Aceclofenac a BCS-II drug, when taken orally, causes first-pass metabolism and partially water-insoluble causing some gastrointestinal (GI) issues. Objective work was preparation evaluation solid lipid nanoparticle for rheumatoid increases drug permeability further possibility to decreasing irritation. M...

The major objective of the current study is to implement a plan enhance dissolution rate and oral bioavailability poorly water-soluble aceclofenac. drug classified according biopharmaceutical classification system as class II drug. Amorphous alkalinized aceclofenac solid dispersion was formulated ternary mixture. This mixture prepared by introducing polymeric carriers [polyvinylpyrrolidone, Hyd...

the aim of this investigation was to prepare, characterize and optimize the aceclofenac proniosomes using central composite design and carry out stability studies. three independent variables selected were molar ratio of drug to lipid (x1), surfactant loading (x2) and volume of hydration (x3). based on central composite design, 16 batches of proniosomes were prepared by slurry method and evalua...

Aceclofenac (AC) is an effective non-steroidal antiinflammatory drug, which possesses remarkable antiinflammatory, analgesic and antipyretic properties. The analgesic and anti-inflammatory efficacy of AC is generally equivalent to that of comparator nonsteroidal antiinflammatory drugs (NSAIDs) with similar onset of action. AC also shows stimulatory effects on glycosaminoglycan synthesis in huma...

   The aim of the present study was to develop a single unit, site-specific matrix tablets of aceclofenac allowing targeted drug release in the colon with a microbially degradable polymeric carrier, chondroitin suphate (CS) and to coat the optimized batches with a pH dependent polymeric. The tablets were prepared by wet granulation method using starch mucilage as a binding agent and HPMC K-100 ...

   The aim of the present study was to develop a single unit, site-specific matrix tablets of aceclofenac allowing targeted drug release in the colon with a microbially degradable polymeric carrier, chondroitin suphate (CS) and to coat the optimized batches with a pH dependent polymeric. The tablets were prepared by wet granulation method using starch mucilage as a binding agent and HPMC K-100 ...